Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses

American Journal of Veterinary Research
Dominique De ClercqPatrick De Backer

Abstract

To determine the clinical effects and pharmacokinetics of amiodarone after single doses of 5 mg/kg administered orally or intravenously. 6 healthy adult horses. In a cross over study, clinical signs and electrocardiographic variables were monitored and plasma and urine samples were collected. A liquid chromatography-mass spectrometry method was used to determine the percentage of protein binding and to measure plasma and urine concentrations of amiodarone and the active metabolite desethylamiodarone. No adverse clinical signs were observed. After IV administration, median terminal elimination half-lives of amiodarone and desethylamiodarone were 51.1 and 75.3 hours, respectively. Clearance was 0.35 L/kg x h, and the apparent volume of distribution for amiodarone was 31.1 L/kg. The peak plasma desethylamiodarone concentration of 0.08 microg/mL was attained 2.7 hours after IV administration. Neither parent drug nor metabolite was detected in urine, and protein binding of amiodarone was 96%. After oral administration of amiodarone, absorption of amiodarone was slow and variable; bioavailability ranged from 6.0% to 33.7%. The peak plasma amiodarone concentration of 0.14 microg/mL was attained 7.0 hours after oral administration and ...Continue Reading

References

Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Jan 1, 1988·Journal of Veterinary Internal Medicine·V B ReefP A Spencer
Mar 1, 1986·The Journal of Clinical Endocrinology and Metabolism·R H RaoG S Spathis
Mar 1, 1982·Journal of Cardiovascular Pharmacology·E RivaA Maggioni
May 1, 1984·Journal of Cardiovascular Pharmacology·S J ConnollyR E Kates
Feb 1, 1983·Drug Intelligence & Clinical Pharmacy·A T CanadaG K Asdourian
Oct 1, 1983·American Heart Journal·B N Singh
Mar 1, 1984·Clinical Pharmacokinetics·R LatiniR E Kates
Oct 1, 1983·American Heart Journal·D W HoltG C Storey
Mar 1, 1981·European Journal of Clinical Pharmacology·F AndreasenH Gøtzsche
Mar 1, 1995·Journal of Veterinary Internal Medicine·V B ReefP A Spencer
Sep 1, 1995·Journal of Veterinary Internal Medicine·C M MarrS W Reid
Jun 1, 1996·The Annals of Pharmacotherapy·M S Chow
Feb 1, 1996·Journal of Clinical Pharmacology·M R UjhelyiM S Chow
May 29, 2000·Journal of Pharmacokinetics and Biopharmaceutics·M Weiss
Jun 29, 2000·Clinical Pharmacology and Therapeutics·P T PollakS L Shafer
Aug 17, 2000·The Journal of Veterinary Medical Science·H OhmuraA Amada
Feb 17, 2001·The American Journal of Cardiology·X MengP R Kowey
Sep 13, 2002·European Journal of Internal Medicine·H AkolJ van der Hoeven
Nov 26, 2002·European Journal of Internal Medicine·Paul R.J. Falger
Oct 8, 2003·Journal of Veterinary Internal Medicine·M Kimberly J McGurrinJ Scott Weese
Apr 3, 2004·Clinical Pharmacology and Therapeutics·P Timothy Pollak, Steven L Shafer
Dec 8, 2004·Current Drug Metabolism·Huy Riem Ha, Ferenc Follath
Dec 8, 2004·Equine Veterinary Journal·G van LoonL E Young

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.